Clinical Trial Update: Rasagiline (Azilect) - Neuroprotection for Macula-off Retinal Detachment [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating rasagiline (Azilect) for neuroprotection in macula-off retinal detachment has been terminated. The study was sponsored by Insel Gruppe …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinal Detachment

Drugs mentioned

• Azilect (rasagiline)

Snippet

Sponsor: Insel Gruppe AG, University Hospital Bern | Conditions: Retinal Detachment | Phase 4 | Status: TERMINATED